Table 2 Prevalence and persistence in use of psychotropic drugs
| Â | Prevalence n (%) | |||||
|---|---|---|---|---|---|---|
A1 | A2 | A3 | ||||
All | D/nD | All | D/nD | All | D/nD | |
(N = 1001) | (N = 415/586) | (N = 599) | (N = 304/295) | (N = 453) | (N = 227/226) | |
Psychotropic drug use | ||||||
Antipsychotics (AP) | 36 (3.6) | 24/12 (5.8/2.0)** | 28 (4.7) | 22/6 (7.2/2.0)** | 30 (6.6) | 26/4 (11.5/1.8)*** |
 Traditional AP | 31 (3.1) | 19/12 (4.6/2.0)* | 23 (3.8) | 17/6 (5.6/2.0)* | 23 (5.1) | 19/4 (8.4/1.8)** |
 Atypical AP | 5 (0.5) | 5/0 (1.2/0) | 6 (1.0) | 6/0 (2.0/0) | 8 (1.8) | 8/0 (3.5/0) |
Antidepressants | 155 (15.5) | 82/73 (19.8/12.5)** | 121 (20.2) | 80/41 (26.3/13.9)*** | 101 (22.3) | 70/31 (30.8/13.7)*** |
Anxiolytics | 86 (8.6) | 43/43 (10.4/7.3) | 71 (11.9) | 48/23 (15.8/7.8)** | 53 (11.7) | 35/18 (15.4/8.0)* |
Sedatives | 221 (22.1) | 103/118 (24.8/20.1) | 128 (21.4) | 78/50 (25.7/16.9)* | 103 (22.7) | 59/44 (26.0/19.5) |
Anti-dementia drugs | 57 (5.7) | 53/4 (12.8/0.7)*** | 60 (10.0) | 57/3 (18.8/1.0)*** | 34 (7.5) | 31/3 (13.7/1.3)*** |
Any PTD | 403 (40.3) | 208/195 (50.1/33.3)*** | 272 (45.4) | 178/94 (58.6/31.9)*** | 210 (46.4) | 132/78 (58.1/34.5)*** |
| Â | Persistence n (%) | |||||
A1-A2 | A2-A3 | |||||
All | D/nD | All | D/nD | |||
Psychotropic drug use | ||||||
Antipsychotics (AP) | 17 (63.0)a | 12/5 (63.2/62.5) | 13 (65.0)a | 10/3 (62.5/75.0) | ||
 Traditional AP | 13 (54.2) | 8/5 (50.0/62.5) | 11 (64.7) | 8/3 (61.5/75.0) | ||
 Atypical AP | 3 (100) | 3/0 (100/0) | 1 (25.0) | 1/0 (25.0/0) | ||
Antidepressants | 83 (82.2) | 45/38 (83.3/80.9) | 69 (82.1) | 41/28 (80.4/84.8) | ||
Anxiolytics | 29 (63.0) | 17/12 (70.8/54.5) | 22 (57.9) | 14/8 (53.8/66.7) | ||
Sedatives | 77 (66.4) | 37/40 (68.5/64.5) | 52 (67.5) | 27/25 (71.1/64.1) | ||
Anti-dementia drugs | 26 (74.3) | 24/2 (75.0/66.7) | 22 (66.7) | 20/2 (64.5/100) | ||
Any PTD | 191 (81.3) | 106/85 (86.9/75.2)* | 142 (83.5) | 85/57 (85.9/80.3) | ||